prajwal reddy retweeted
What can photon-counting CT offer interventional cardiology?
This new expert review explores its potential from lesion assessment to procedural planning, and what remains to be demonstrated.
Read more: eurointervention.pcronline.c…
@gpontone1 @DAndreiniMD @PalMaurovich @OnumaYoshinobu @FCademartiri
Excited to share our early proof of concept work exploring humanoid robot echocardiography (supervised).
Our vision is a multi-use robotic platform that could extend the reach of trained sonographers and clinicians in the Cath lab, remote settings, and reduce orthopaedic injuries.@aelsab @guy_robinson_ @Grace_Lin_MD @JaeKOh2 @pattypellikka @kylalaraMD @mmartinezheart @purviparwani @JeremyThaden
sciencedirect.com/science/au…
prajwal reddy retweeted
At #TCT2026 we showcased the use of a humanoid robot in the cath lab to increase procedural efficiency, with simultaneous publication in @EuroInterventio
@aelsab
@MaryHedgesMD
@MayraGuerreroMD
@DFCapodanno
@rajivxgulati
@mirvatalasnag
@mmamas1973
eurointervention.pcronline.c…
Presented at #ESCCongress:
In patients with suspected acute coronary syndrome without myocardial infarction, routine CT coronary angiography did not result in a lower incidence of myocardial infarction or death from a cardiac cause than standard care. Full TARGET-CTCA trial results: nej.md/4wH7Yk7
@escardio

ALT A figure from the Original Article "Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain." The trial name, TARGET-CTCA, is in parentheses after the title. The figure shows the incidence of myocardial infarction or death from a cardiac cause. The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.
MAvERIC Trial: In recurrent pericarditis patients treated with synthetic cannabidiol, pericarditis pain and inflammation decreased. @MayoClinicCV ahajrnls.org/44Xhx2R
prajwal reddy retweeted
Replying to @PWesslyMD @LucySafi @PriyaPanday27 @NadeenFaza @ASE360 @JournalASEcho @DavidWienerMD @iamritu @purviparwani @SIwa23288585 @boegel_kelly
MAD is a true separation between the LV crest & posterior mitral leaflet/LA junction. Pseudo-MAD mimics this during systole when a voluminous leaflet presses against the LA wall, but it vanishes in diastole. Distinguishing them is key! #ASEchoJC
prajwal reddy retweeted
🩺 Managing pericarditis in patients with cancer risk? #CardioOnc
Don’t let risk hold back treatment. Our latest manuscript provides a new framework to guide biologic therapy decision-making and ensure viable options for RP patients.
Read more: sciencedirect.com/science/ar…
prajwal reddy retweeted
Explore practical and advanced multimodality imaging—echo, nuclear, CT, and CMR—to support diagnosis, risk stratification, and management across cardiovascular disease in modern #cvImaging and #Cardiology practice: mayocl.in/4uoLtQ5 @DrAmyPollak @PanithayaC
prajwal reddy retweeted
📢 New study! 🤖🫀 A deep learning model can fully automatically quantify LV, LA & LAA function from CT scans, offering fast, reliable measures of cardiac volumes and ejection metrics — boosting reproducibility and reducing manual effort in heart function assessment. 🩺🧠
#EHJIMP #CardioAI #CTimaging #HeartFunction #AIinMedicine @jgrapsa @saramoscatelli7 @alessia_gimelli @EHJIMPEiC @EACVIPresident ow.ly/hHHS50XN1Ti
prajwal reddy retweeted
DeviceGuide: AI tool for M-TEER Guidance! See the JACC Case Series authors.elsevier.com/sd/arti… @JACCJournals @GilbertTangMD @ACCinTouch @escardio
prajwal reddy retweeted
Myocarditis and Pericarditis in Focus
A Brief Report Comparing the 2025 ESC Guidelines and Latest ACC Position Papers. Learn more in J Am Coll Cardiol
2025 Nov 19:S0735-1097(25)10033-8.
doi: 10.1016/j.jacc.2025.10.047
prajwal reddy retweeted
Quantitative Coronary Plaque Analysis (QCPA): promise, but also important pitfalls — a critical reading of the 2025 ACC Scientific Statement
The 2025 ACC Scientific Statement on Quantitative Coronary Plaque Analysis (QCPA) is an important step toward integrating AI-driven plaque quantification into clinical cardiology. However, the document also implicitly reveals several major weaknesses and unresolved pitfalls that deserve explicit attention before widespread adoption .
1. Reproducibility across platforms remains a major Achilles’ heel
QCPA results are not interchangeable across vendors or software versions. Different algorithms use distinct lumen–wall segmentation methods, HU thresholds, training datasets, and post-processing rules. As a result, total plaque volume and plaque composition can differ substantially between platforms—even when analyzing the same scan. True cross-vendor standardization is still lacking.
2. CT acquisition parameters strongly influence plaque quantification
Plaque volumes and composition are highly sensitive to scan parameters, including:
Tube voltage (kVp)
Reconstruction kernel and slice thickness
Iterative vs deep-learning reconstruction
Scanner generation (energy-integrating vs photon-counting CT)
Small technical differences can translate into artificial changes in plaque volume or composition, particularly for non-calcified and low-attenuation plaque—precisely the components most often linked to risk.
3. Serial QCPA is biologically appealing but methodologically fragile
The statement rightly discourages routine serial QCPA. Even with the same patient, apparent plaque “progression” may reflect technical variability rather than biology, unless acquisition and reconstruction are rigorously matched. Proposed progression thresholds (e.g. ΔTPV 10–20 mm³/year) remain expert opinion, not outcome-validated cut-offs.
4. Risk of overcalling subvisual plaque
This is particularly tricky since conventional CT technology (with few exception in the current market namely Cleerly) is not able to properly set the lower threshold for normal coronary artery wall volume.
AI-based QCPA frequently detects plaque volumes below visual thresholds. The clinical significance of minimal plaque (<20–30 mm³) is unknown and risks overdiagnosis, overtreatment, and patient anxiety, especially in low-risk populations.
5. Outcome evidence is still indirect
While plaque burden correlates with risk, no randomized trial has yet demonstrated that QCPA-guided management improves outcomes beyond standard CTA interpretation, CAC scoring, and clinical risk assessment.
Bottom line:
QCPA is a powerful research and risk-phenotyping tool, but today it remains technically sensitive, platform-dependent, and insufficiently standardized. Until reproducibility, calibration, and outcome validation improve, QCPA should be used selectively, cautiously, and always interpreted in clinical context—not as a standalone decision-maker.
prajwal reddy retweeted
Scoring Systems for Pericarditis: A Step Toward Structured Risk Stratification. Learn more on Current Cardiology Reports (2025) 27:101. doi.org/10.1007/s11886-025-0…
prajwal reddy retweeted
SLDA during tTEER presents a sig. procedural challenge but can be managed effectively with clip retrieval using the EN Snare & ŌNŌ devices. Both cases demonstrated successful clip retrieval w/out injury to valve leaflets & successful #TEER jacc.org/doi/10.1016/j.jacca… #JACCCaseReports
prajwal reddy retweeted
Loose tricuspid SLDA? ONO facilitated retrieval: jacc.org/doi/10.1016/j.jacca…
ONO basket allows stand up of snared clip vertically allowing smooth retrieval into sheath without getting stuck perpendicularly at sheath entry/injury to vein @SinaOSullivan @mirvatalasnag @DrPeterPollak
prajwal reddy retweeted
🔴Cardiovascular MRI in mitral valve disease⤵️State of the Art #2024Review #OpenAccess
🔹academic.oup.com/eurheartj/a…
#Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros #MedX #cardiovascular
prajwal reddy retweeted
In #AFMR, atriogenic hamstringing shows worse procedural results than isolated annular dilation after #MTEER. jacc.org/doi/10.1016/j.jcmg.…
#JACCIMG #cvImaging @hahn_rt @chriliadis @HWienemann @JennifervStein @philippvstein @HenningGuthoff





























